检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《实用肿瘤杂志》2010年第5期534-538,共5页Journal of Practical Oncology
摘 要:目的分析卵巢内胚窦瘤的临床病理学特点,以及Bc l-2在卵巢内胚窦瘤中的表达,探讨影响该病预后的相关因素。方法回顾性分析辽宁省肿瘤医院1984年1月至2007年12月收治的76例卵巢内胚窦瘤患者的临床病理学资料,分析Bc l-2在卵巢内胚窦瘤中的表达,了解各临床病理因素对预后的影响。结果Ⅰ、Ⅱ、Ⅲ及Ⅳ期卵巢内胚窦瘤患者的5年生存率分别为91.8%、88.9%、39.5%及25.0%。年龄、组织学类型、术前血清中甲胎蛋白值水平、是否保留生育功能的手术方式、术前肿瘤大小并不影响该病的预后。以铂类为基础的化疗方案,化疗疗程数>3,残余瘤直径≤2 cm和腹水量≤100 mL是影响预后的因素。Bc l-2在不同病理类型间表达差异有统计学意义(P<0.05),但Bc l-2并不是影响预后的独立因素。结论临床分期,以铂类为基础的化疗方案,化疗疗程数,残余瘤直径和腹水量是影响预后的因素。Objective To investigate the expression of Bcl-2 and prognostic factors of ovarian yolk sac tumors(YST).Methods Seventy-six patients with ovarian YST from Department of Obstetrics and Gynecology,Liaoning Cancer Hospital Institute between 1984 and 2007 were retrospectively reviewed.The expression of Bcl-2 was investigated by immunochemistry.Results The 5-year overall survival rates in stage Ⅰ,Ⅱ,Ⅲ and Ⅳ were 91.8%,88.9%,39.5%,and 25.0%,respectively.Age,histologic type,preoperative serum α-fetoprotein(AFP) level,fertility-sparing surgery and tumor size did not affect the prognosis of YST.Cisplatin-based chemotherapy,chemotherapy courses3,residual tumor ≤2 cm and ascites volume ≤100 mL were the predictors for overall survival.Bcl-2 was not the predicton affecting the prognosis of YST.Conclusion Cisplatin-based chemotherapy,chemotherapy courses,residual tumor size and ascites volume are prognosis factors.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.90